✦ LIBER ✦

Safe conversion from cyclosporine to azathioprine with improved renal function in pediatric renal transplantation

✍ Scribed by Bruce A. Kaiser; Stephen T. Lawless; JoAnn M. Palmer; Stephen P. Dunn; Martin S. Polinsky; H. Jorge Baluarte

Publisher: Springer
Year: 1989
Tongue: English
Weight: 520 KB
Volume: 3
Category: Article
ISSN: 0931-041X
DOI: 10.1007/bf00850215

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Changes in immunological parameters afte

Changes in immunological parameters after conversion from cyclosporine A to azathioprine in renal transplant recipients

✍ D.J. Versluis; A.M. Bijma; L.M.B. Vaessen; W. Weimar 📂 Article 📅 1989 🏛 Elsevier Science 🌐 English ⚖ 555 KB

Improvement of renal function after the

Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction

✍ Javier F. Castroagudín; Esther Molina; Rafael Romero; Esteban Otero; Santiago To 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 141 KB 👁 1 views

Chronic renal dysfunction is a frequent and severe complication in solid-organ transplant recipients. Calcineurin inhibitors (CNIs) are the main pathogenic factors of renal dysfunction. Switching from CNIs to nonnephrotoxic drugs, such as mammalian target of rapamycin inhibitors (everolimus and siro

Switch to 1.5 grams MMF monotherapy for

Switch to 1.5 grams MMF monotherapy for CNI-related toxicity in liver transplantation is safe and improves renal function, dyslipidemia, and hypertension

✍ Giuseppe Orlando; Leonardo Baiocchi; Andrea Cardillo; Giuseppe Iaria; Nicola De 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 182 KB

Although mycophenolate mofetil (MMF) monotherapy has been successfully used in liver transplant recipients suffering from calcineurin-inhibitor (CNI)-related chronic toxicity, still no consensus has been reached on its safety, efficacy and tolerability. We attempted the complete weaning off CNI in 4

A randomized controlled trial of late co

A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function

✍ Christopher J.E. Watson; Alexander E.S. Gimson; Graeme J. Alexander; Michael E.D 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 307 KB 👁 1 views

Renal impairment is common in patients after liver transplantation and is attributable in large part to the use of calcineurin inhibitor (CNI)-based immunosuppression. We sought to determine whether conversion to sirolimus-based immunosuppression was associated with improved renal function. In a sin